Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset
Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S2666328726001367?dgcid=rss_sd_all
Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset. JAAD International. https://www.sciencedirect.com/science/article/pii/S2666328726001367?dgcid=rss_sd_all
“Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset.” JAAD International.
@article{article118899,
title = {Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S2666328726001367?dgcid=rss_sd_all}
}